Pharmacokinetics and pharmacodynamics of high-dose human regular U-500 insulin versus human regular U-100 insulin in healthy obese subjects

Diabetes Care

Volumn 34, Issue 12, 2011, Pages 2496-2501

  De La Peña, Amparo ^a   Riddle, Matthew ^b   Morrow, Linda A ^c   Jiang, Honghua H ^a   Linnebjerg, Helle ^a   Scott, Adam ^a   Win, Khin M ^c   Hompesch, Marcus ^c   Mace, Kenneth F ^a   Jacobson, Jennie G ^d   Jackson, Jeffrey A ^d  

^a ELI LILLY AND COMPANY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c Profil Institute for Clinical Research   (United States)

^d Lilly USA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HUMAN INSULIN; ANTIDIABETIC AGENT;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRUG HALF LIFE; DRUG MEGADOSE; FEMALE; GLUCOSE CLAMP TECHNIQUE; HEADACHE; HUMAN; MALE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; OBESITY; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; AGED; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG EFFECT; GLUCOSE BLOOD LEVEL; MIDDLE AGED;

ADULT; AGED; AREA UNDER CURVE; BLOOD GLUCOSE; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; GLUCOSE CLAMP TECHNIQUE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN, REGULAR, HUMAN; MALE; MIDDLE AGED; OBESITY;

EID: 84860873383     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc11-0721     Document Type: Article

References (25)

1. IMS Health. National Prescription Audit Monthly, January 2007-August 2010. Data on file, Eli Lilly and Company, Indianapolis, IN
2. Knee TS, Seidensticker DF, Walton JL, Solberg LM, Lasseter DH. A novel use of U-500 insulin for continuous subcutaneous insulin infusion in patients with insulin resistance: a case series. Endocr Pract 2003;9:181-186
3. Cochran E, Musso C, Gorden P. The use of U-500 in patients with extreme insulin resistance. Diabetes Care 2005;28:1240-1244 (Pubitemid 40616647)
4. Ballani P, Tran MT, Navar MD, Davidson MB. Clinical experience with U-500 regular insulin in obese, markedly insulinresistant type 2 diabetic patients. Diabetes Care 2006;29:2504-2505 (Pubitemid 44912260)
5. Lane WS, Cochran EK, Jackson JA, et al. High-dose insulin therapy: is it time for U-500 insulin? Endocr Pract 2009;15: 71-79
6. Dailey AM, Williams S, Taneja D, Tannock LR. Clinical efficacy and patient satisfaction with U-500 insulin use. Diabetes Res Clin Pract 2010;88:259-264
7. Davidson MB, Navar MD, Echeverry D, Duran P. U-500 regular insulin: clinical experience and pharmacokinetics in obese, severely insulin-resistant type 2 diabetic patients. Diabetes Care 2010;33:281-283
8. Lane WS, Weinrib SL, Rappaport JM, Przestrzelski T. A prospective trial of U500 insulin delivered by Omnipod in patients with type 2 diabetes mellitus and severe insulin resistance. Endocr Pract 2010;16: 778-784
9. Khan M, Lee YY. The pharmacokinetic and pharmacodynamic properties of regular U-500 insulin in healthy non-obese subjects (Abstract). Diabetes 2007;56(Suppl. 1): A334-A335
10. Khan MI, Sarabu B. The pharmacokinetic and pharmacodynamic properties of regular U-500 insulin in healthy obese subjects (Abstract). Diabetes 2009;58(Suppl. 1): A601
11. American Diabetes Association. Standards of medical care in diabetes - 2010. Diabetes Care 2010;33(Suppl. 1):S11-S61
12. Heinemann L. Time-action profiles of insulin preparations. Mainz, Germany, Kirchheim & Co. GmbH, 2004
13. Binder C, Lauritzen T, FaberO, Pramming S. Insulin pharmacokinetics. Diabetes Care 1984;7:188-199 (Pubitemid 14137203)
14. Jørgensen KH, Hansen AK, Buschard K. Five fold increase of insulin concentration delays the absorption of subcutaneously injected human insulin suspensions in pigs. Diabetes Res Clin Pract 2000;50: 161-167
15. Galloway JA, Spradlin CT, Nelson RL, Wentworth SM, Davidson JA, Swarner JL. Factors influencing the absorption, serum insulin concentration, and blood glucose responses after injections of regular insulin and various insulin mixtures. Diabetes Care 1981;4:366-376 (Pubitemid 12201586)
16. Binder C. Absorption of injected insulin. A clinical-pharmacological study. Acta Pharmacol Toxicol (Copenh) 1969;27 (Suppl. 2):1-84
17. Hildebrandt P, Sestoft L, Nielsen SL. The absorption of subcutaneously injected short-acting soluble insulin: influence of injection technique and concentration. Diabetes Care 1983;6:459-462 (Pubitemid 13005552)
18. Trajanoski Z, Wach P, Kotanko P, Ott A, Skraba F. Pharmacokinetic model for the absorption of subcutaneously injected soluble insulin and monomeric insulin analogues. Biomed Tech (Berl) 1993;38:224-231 (Pubitemid 23291519)
19. Heinemann L, Woodworth J. Pharmacokinetics and glucodynamics of insulin lispro. Drugs Today (Barc) 1998;34 (Suppl. C):23-36 (Pubitemid 28238101)
20. Klein O, Lynge J, Endahl L, Damholt B, Nosek L, Heise T. Albumin-bound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetes. Diabetes Obes Metab 2007;9:290-299 (Pubitemid 46502046)
21. Hompesch M, Ocheltree SM, Wondmagegnehu ET, et al. Pharmacokinetics and pharmacodynamics of insulin lispro protamine suspension compared with insulin glargine and insulin detemir in type 2 diabetes. Curr Med Res Opin 2009;25:2679-2687
22. Gagnon-Auger M, du Souich P, Baillargeon JP, et al. Dose-dependent delay of the hypoglycemic effect of short-acting insulin analogs in obese subjects with type 2 diabetes: a pharmacokinetic and pharmacodynamic study. Diabetes Care 2010;33: 2502-2507
23. Eli Lilly and Company. Humulin R (product label) [Internet], 2010. Indianapolis, IN. Available fromhttp://www.accessdata.fda.gov/ drugsatfda-docs/label/2010/018780s128lbl. pdf. Accessed 20 September 2010
24. Cochran E, Gorden P. The use of U-500 insulin in the treatment of severe insulin resistance. Insulin 2008;3:211-218
25. Segal AR, Brunner JE, Burch FT, Jackson JA. Use of concentrated insulin human regular (U-500) for patients with diabetes. Am J Health Syst Pharm 2010;67:1526-1535